Age-related differences in patch testing results among children: Analysis of North American Contact Dermatitis Group Data, 2001-2018.
adolescent
allergic contact dermatitis
children
dermatitis
epidemiology
health
itch
patch test
pruritus
rash
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
23
03
2021
revised:
08
07
2021
accepted:
15
07
2021
pubmed:
28
7
2021
medline:
15
4
2022
entrez:
27
7
2021
Statut:
ppublish
Résumé
An updated understanding of allergic contact dermatitis is needed, particularly in children. To compare positive and clinically relevant reactions in children versus adults referred for patch testing. Retrospective analysis of 1871 children and 41,699 adults from the North American Contact Dermatitis Group (NACDG) from 2001-2018. Both final diagnosis of allergic contact dermatitis (55.2% versus 57.3%; chi square, P = .0716) and prevalence of ≥ 1 currently relevant reaction to a NACDG screening allergen (49.2% vs 52.2%; P = .1178) were similar between children and adults. Currently in children, the most common relevant allergens were nickel sulfate (17.3%), hydroperoxides of linalool (7.8%), methylisothiazolinone (7.7%), cobalt chloride (7.0%), and fragrance mix I (4.9%). Approximately a fifth of children had a positive reaction to a non-NACDG allergen. Over half of children referred for patch testing were diagnosed with allergic contact dermatitis. The most common relevant allergens in children were nickel sulfate, cobalt chloride, and hydroperoxides of linalool. Twenty percent of children had at least 1 positive reaction to allergens/substances not on the NACDG screening series, underscoring the need for comprehensive testing.
Sections du résumé
BACKGROUND
An updated understanding of allergic contact dermatitis is needed, particularly in children.
OBJECTIVES
To compare positive and clinically relevant reactions in children versus adults referred for patch testing.
METHODS
Retrospective analysis of 1871 children and 41,699 adults from the North American Contact Dermatitis Group (NACDG) from 2001-2018.
RESULTS
Both final diagnosis of allergic contact dermatitis (55.2% versus 57.3%; chi square, P = .0716) and prevalence of ≥ 1 currently relevant reaction to a NACDG screening allergen (49.2% vs 52.2%; P = .1178) were similar between children and adults. Currently in children, the most common relevant allergens were nickel sulfate (17.3%), hydroperoxides of linalool (7.8%), methylisothiazolinone (7.7%), cobalt chloride (7.0%), and fragrance mix I (4.9%). Approximately a fifth of children had a positive reaction to a non-NACDG allergen.
CONCLUSION
Over half of children referred for patch testing were diagnosed with allergic contact dermatitis. The most common relevant allergens in children were nickel sulfate, cobalt chloride, and hydroperoxides of linalool. Twenty percent of children had at least 1 positive reaction to allergens/substances not on the NACDG screening series, underscoring the need for comprehensive testing.
Identifiants
pubmed: 34314743
pii: S0190-9622(21)02178-2
doi: 10.1016/j.jaad.2021.07.030
pii:
doi:
Substances chimiques
Allergens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
818-826Informations de copyright
Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest This study was supported by resources and use of facilities at the Minneapolis Veterans Affairs Medical Center. The contents do not represent the views of the US Department of Veterans Affairs or the US Government. Dr Sasseville receives royalties from UpToDate (Wolters Kluwer Health). Dr Taylor owns noncontrolling common stock in Cigna, Merck, Johnson and Johnson, Astra Zeneca, and Opko Health; is a member of the Cosmetic Ingredient Review Steering Committee; and has a nondependent child who is employed by Pfizer. Dr Warshaw has served as a consultant for Wen by Chaz Dean and Noven Pharmaceuticals and is grant funded by Wen by Chaz Dean. Dr Atwater received a Pfizer Independent Grant for Learning & Change and has consulted for Henkel.